Personalized Strategies to Manage Symptoms of Chronic Illness (R15) | PA 16 006

Frequently Asked Questions (FAQs)

What is the NIH funding opportunity "Personalized Strategies to Manage Symptoms of Chronic Illness (R15)"?

This NIH opportunity (Funding Opportunity Number PA-16-006) supports interdisciplinary research focused on reducing the day-to-day symptom burden experienced by people living with chronic illnesses, with the goal of improving health-related quality of life (HRQL). It encourages moving beyond one-size-fits-all approaches by developing more personalized, targeted strategies to prevent symptoms, reduce symptom severity, or improve symptom self-management.

What is the main goal of this grant?

The central goal is to improve the lived experience of chronic illness by (1) strengthening scientific understanding of the biological mechanisms that drive common and debilitating symptoms, and (2) designing and testing innovative, targeted, and cost-effective interventions that can meaningfully reduce symptom burden and improve HRQL.

What kinds of research projects are a fit for this opportunity?

Projects may include mechanistic studies that clarify why symptoms occur and intervention studies that translate symptom science into practical management strategies. The announcement emphasizes both symptom biology (understanding pathways that contribute to symptoms) and pragmatic symptom management (developing and testing strategies that can be implemented in real-world clinical or community settings).

Does the opportunity focus more on symptom science or on interventions?

It supports both. The opportunity describes two connected tracks: building stronger scientific understanding of symptom mechanisms and designing/testing cost-effective interventions informed by that understanding.

What symptoms are highlighted as examples in the announcement?

Examples include fatigue, pain, sleep disturbance, cognitive changes, and mood-related symptoms. The announcement frames these as common and debilitating symptoms that can disrupt functioning and well-being in chronic conditions.

What biological mechanisms or pathways are mentioned as relevant?

The opportunity provides examples of biological pathways that may contribute to symptoms, including inflammatory, neuroendocrine, genetic, and other biological mechanisms.

What does "personalized strategies" mean in this context?

It refers to developing more targeted approaches to symptom prevention and management rather than relying on a one-size-fits-all model. The intention is to address the symptoms that most disrupt an individual's functioning and quality of life, using strategies informed by symptom mechanisms.

Why does the announcement emphasize "cost-effective" interventions?

The wording signals interest in approaches with a credible path to scalability and real-world impact, not just proof-of-concept ideas that would be difficult to implement broadly in clinical or community settings.

What grant mechanism is used for this opportunity?

This is an NIH R15 funding opportunity. The R15 mechanism is part of NIH's research grant portfolio and is commonly associated with supporting research and research capacity building in eligible institutions.

What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA number 93.361.

What is the maximum award amount mentioned?

The posted award ceiling in the source data is $300,000, indicating an upper bound on the total budget NIH expects to support per award under this announcement.

When was this opportunity created and what closing date is listed?

The opportunity record was created on October 16, 2015, and the original closing date shown in the source data is December 18, 2017.

Should applicants rely on the listed closing date?

No. The information notes that applicants should verify current due dates and the active status in the full announcement and on NIH systems, since NIH opportunities may have multiple receipt dates or may be superseded by later announcements.

Who is eligible to apply?

Eligibility is broad and includes many U.S.-based organizations and governmental units. Examples listed include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; small businesses; and other entities.

Are minority-serving and specialized institutions specifically mentioned as eligible?

Yes. The announcement explicitly calls out categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).

Are faith-based or community-based organizations eligible?

Yes. The eligible categories listed include faith-based or community-based organizations.

Are U.S. territories or possessions included in eligibility?

Yes. U.S. territories or possessions are explicitly mentioned among the eligible categories.

Can federal agencies apply?

Eligible federal agencies are explicitly listed among the additional eligible categories.

Are non-U.S. (foreign) organizations eligible to apply?

No. Non-domestic (non-U.S.) entities are not eligible to apply under this opportunity.

Are non-domestic components of U.S. organizations eligible to apply?

No. Non-domestic components of U.S. organizations are not eligible to apply.

Are "foreign components" allowed at all?

Yes. The announcement notes that foreign components (as defined in the NIH Grants Policy Statement) are allowed. This generally means the applicant organization must be U.S.-based and eligible, while certain elements of the project may involve international collaboration if they meet NIH's definition and requirements for a foreign component.

What should applicants do if their project involves international collaboration?

The information provided flags that there are special requirements and directs applicants to consult the full announcement for details. Applicants should ensure any international element meets NIH's definition of a foreign component and complies with NIH requirements described in the full announcement and policy guidance.

What subject areas does this opportunity fall under?

It is categorized under Education and Health.

What makes an application competitive based on the description?

Based on the description, competitive applications are likely to (1) align symptom mechanism questions with a clear plan for translating findings into targeted management strategies, (2) demonstrate interdisciplinary expertise, and (3) justify feasibility and cost-conscious implementation while aiming for measurable improvements in symptom burden and HRQL.

Does the announcement require interdisciplinary teams?

It supports interdisciplinary research and is designed for teams that can blend biological insight with pragmatic intervention development to improve symptom outcomes and HRQL.

Does the opportunity prioritize real-world implementation?

Yes. The emphasis on targeted, cost-effective interventions and scalability suggests NIH is looking for strategies that can credibly be implemented broadly in clinical or community settings.

Where should applicants look for the most authoritative requirements and rules?

The description indicates that applicants should consult the full announcement for details, including allowable costs, project scope, review criteria, reporting expectations, and any program-specific rules tied to the R15 mechanism, and also verify current receipt dates and active status through NIH systems.